In new deal, AstraZeneca places small bet on 'critical but challenging' target
AstraZeneca has its eyes on NRF2 as a target for inflammatory and respiratory diseases, and it’s handing out $2 million in cash to pluck a preclinical candidate from a drug discovery shop.
It’s so early that C4X Discovery doesn’t have a name for the oral NRF2 activator program just yet. Including the upfront, the biotech is eligible for a total of $16 million in preclinical payments, after which AstraZeneca will take over for clinical development and commercialization. Those future milestones add up to $385.8 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.